Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (5): 399-404.DOI: 10.3969/j.issn.1673-8640.2020.05.001
JIANG Wenrong, MIAO Yingxin, WANG Su, WANG Shiwen, ZHAO Hu, ZHANG Yanmei()
Received:
2019-11-13
Online:
2020-05-30
Published:
2020-06-17
CLC Number:
JIANG Wenrong, MIAO Yingxin, WANG Su, WANG Shiwen, ZHAO Hu, ZHANG Yanmei. Influence of common clinical interference factors on the detection of ctDNA EGFR T790M mutation[J]. Laboratory Medicine, 2020, 35(5): 399-404.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.05.001
组别 | 胆红素/ (μmol/L) | 血红蛋白/ (g/L) | 三酰甘油/ (mmol/L) |
---|---|---|---|
黄疸组 | |||
低干扰组 | 85.5 | ||
中度干扰组 | 171.0 | ||
较高干扰组 | 256.5 | ||
高干扰组 | 342.0 | ||
溶血组 | |||
低干扰组 | 0.5 | ||
中度干扰组 | 1.0 | ||
较高干扰组 | 1.5 | ||
高干扰组 | 2.0 | ||
脂血组 | |||
低干扰组 | 9.25 | ||
中度干扰组 | 18.50 | ||
较高干扰组 | 27.75 | ||
高干扰组 | 37.00 |
组别 | 胆红素/ (μmol/L) | 血红蛋白/ (g/L) | 三酰甘油/ (mmol/L) |
---|---|---|---|
黄疸组 | |||
低干扰组 | 85.5 | ||
中度干扰组 | 171.0 | ||
较高干扰组 | 256.5 | ||
高干扰组 | 342.0 | ||
溶血组 | |||
低干扰组 | 0.5 | ||
中度干扰组 | 1.0 | ||
较高干扰组 | 1.5 | ||
高干扰组 | 2.0 | ||
脂血组 | |||
低干扰组 | 9.25 | ||
中度干扰组 | 18.50 | ||
较高干扰组 | 27.75 | ||
高干扰组 | 37.00 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
DNA浓度/(ng/μL) | P值 | DNA浓度/(ng/μL) | P值 | |
空白组 | 9.7±1.3 | 14.6±4.3 | ||
黄疸组 | ||||
低干扰组 | 14.7±4.8 | 0.005 | 11.9±3.2 | 0.013 |
中度干扰组 | 13.5±1.6 | 0.002 | 12.9±5.2 | 0.266 |
较高干扰组 | 14.2±2.3 | 0.002 | 21.2±18.0 | 0.224 |
高干扰组 | 14.7±2.7 | 0.002 | 14.0±4.9 | 0.669 |
溶血组 | ||||
低干扰组 | 12.1±3.1 | 0.109 | 12.3±1.5 | 0.135 |
中度干扰组 | 13.0±5.1 | 0.129 | 12.4±2.6 | 0.125 |
较高干扰组 | 13.3±5.3 | 0.139 | 12.1±1.9 | 0.101 |
高干扰组 | 11.3±2.0 | 0.153 | 11.9±1.5 | 0.037 |
脂血组 | ||||
低干扰组 | 15.4±3.3 | 0.001 | 15.3±5.2 | 0.827 |
中度干扰组 | 16.3±4.2 | 0.001 | 17.9±6.5 | 0.354 |
较高干扰组 | 17.6±6.9 | 0.006 | 21.3±10.9 | 0.181 |
高干扰组 | 19.9±8.4 | 0.006 | 23.5±11.9 | 0.116 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
DNA浓度/(ng/μL) | P值 | DNA浓度/(ng/μL) | P值 | |
空白组 | 9.7±1.3 | 14.6±4.3 | ||
黄疸组 | ||||
低干扰组 | 14.7±4.8 | 0.005 | 11.9±3.2 | 0.013 |
中度干扰组 | 13.5±1.6 | 0.002 | 12.9±5.2 | 0.266 |
较高干扰组 | 14.2±2.3 | 0.002 | 21.2±18.0 | 0.224 |
高干扰组 | 14.7±2.7 | 0.002 | 14.0±4.9 | 0.669 |
溶血组 | ||||
低干扰组 | 12.1±3.1 | 0.109 | 12.3±1.5 | 0.135 |
中度干扰组 | 13.0±5.1 | 0.129 | 12.4±2.6 | 0.125 |
较高干扰组 | 13.3±5.3 | 0.139 | 12.1±1.9 | 0.101 |
高干扰组 | 11.3±2.0 | 0.153 | 11.9±1.5 | 0.037 |
脂血组 | ||||
低干扰组 | 15.4±3.3 | 0.001 | 15.3±5.2 | 0.827 |
中度干扰组 | 16.3±4.2 | 0.001 | 17.9±6.5 | 0.354 |
较高干扰组 | 17.6±6.9 | 0.006 | 21.3±10.9 | 0.181 |
高干扰组 | 19.9±8.4 | 0.006 | 23.5±11.9 | 0.116 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
A260/A280 | P值 | A260/A280 | P值 | |
空白组 | 2.27±0.50 | 1.73±0.15 | ||
黄疸组 | ||||
低干扰组 | 2.24±0.19 | 0.846 | 1.86±0.25 | 0.098 |
中度干扰组 | 2.16±0.16 | 0.554 | 1.82±0.08 | 0.159 |
较高干扰组 | 2.12±0.14 | 0.472 | 1.78±0.11 | 0.308 |
高干扰组 | 2.08±0.10 | 0.286 | 1.74±0.10 | 0.813 |
溶血组 | ||||
低干扰组 | 2.11±0.15 | 0.346 | 1.99±0.35 | 0.010 |
中度干扰组 | 2.13±0.24 | 0.393 | 1.92±0.35 | 0.037 |
较高干扰组 | 2.16±0.34 | 0.555 | 1.91±0.30 | 0.031 |
高干扰组 | 2.15±0.33 | 0.632 | 1.99±0.53 | 0.106 |
脂血组 | ||||
低干扰组 | 2.07±0.22 | 0.293 | 2.35±0.29 | 0.000 |
中度干扰组 | 2.19±0.36 | 0.616 | 2.20±0.19 | 0.000 |
较高干扰组 | 2.19±0.44 | 0.613 | 2.21±0.38 | 0.001 |
高干扰组 | 2.19±0.25 | 0.607 | 2.24±0.48 | 0.003 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
A260/A280 | P值 | A260/A280 | P值 | |
空白组 | 2.27±0.50 | 1.73±0.15 | ||
黄疸组 | ||||
低干扰组 | 2.24±0.19 | 0.846 | 1.86±0.25 | 0.098 |
中度干扰组 | 2.16±0.16 | 0.554 | 1.82±0.08 | 0.159 |
较高干扰组 | 2.12±0.14 | 0.472 | 1.78±0.11 | 0.308 |
高干扰组 | 2.08±0.10 | 0.286 | 1.74±0.10 | 0.813 |
溶血组 | ||||
低干扰组 | 2.11±0.15 | 0.346 | 1.99±0.35 | 0.010 |
中度干扰组 | 2.13±0.24 | 0.393 | 1.92±0.35 | 0.037 |
较高干扰组 | 2.16±0.34 | 0.555 | 1.91±0.30 | 0.031 |
高干扰组 | 2.15±0.33 | 0.632 | 1.99±0.53 | 0.106 |
脂血组 | ||||
低干扰组 | 2.07±0.22 | 0.293 | 2.35±0.29 | 0.000 |
中度干扰组 | 2.19±0.36 | 0.616 | 2.20±0.19 | 0.000 |
较高干扰组 | 2.19±0.44 | 0.613 | 2.21±0.38 | 0.001 |
高干扰组 | 2.19±0.25 | 0.607 | 2.24±0.48 | 0.003 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
内控Ct值 | P值 | 内控Ct值 | P值 | |
空白组 | 15.95±0.69 | / | 14.59±0.64 | / |
黄疸组 | ||||
低干扰组 | 15.62±0.26 | 0.243 | 14.54±0.58 | 0.626 |
中度干扰组 | 15.69±0.74 | 0.456 | 14.40±0.52 | 0.113 |
较高干扰组 | 15.72±0.71 | 0.550 | 14.32±0.52 | 0.040 |
高干扰组 | 15.71±0.75 | 0.517 | 14.30±0.57 | 0.020 |
溶血组 | ||||
低干扰组 | 15.76±0.43 | 0.418 | 14.63±0.86 | 0.790 |
中度干扰组 | 15.75±0.54 | 0.520 | 14.44±0.46 | 0.169 |
较高干扰组 | 15.74±0.77 | 0.585 | 14.49±0.52 | 0.213 |
高干扰组 | 15.91±0.56 | 0.892 | 14.38±0.64 | 0.135 |
脂血组 | ||||
低干扰组 | 14.43±0.52 | 0.000 | 14.12±0.55 | 0.011 |
中度干扰组 | 14.37±0.44 | 0.000 | 13.89±0.62 | 0.000 |
较高干扰组 | 14.61±0.24 | 0.001 | 14.26±0.37 | 0.049 |
高干扰组 | 14.31±0.41 | 0.000 | 13.93±0.46 | 0.001 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
内控Ct值 | P值 | 内控Ct值 | P值 | |
空白组 | 15.95±0.69 | / | 14.59±0.64 | / |
黄疸组 | ||||
低干扰组 | 15.62±0.26 | 0.243 | 14.54±0.58 | 0.626 |
中度干扰组 | 15.69±0.74 | 0.456 | 14.40±0.52 | 0.113 |
较高干扰组 | 15.72±0.71 | 0.550 | 14.32±0.52 | 0.040 |
高干扰组 | 15.71±0.75 | 0.517 | 14.30±0.57 | 0.020 |
溶血组 | ||||
低干扰组 | 15.76±0.43 | 0.418 | 14.63±0.86 | 0.790 |
中度干扰组 | 15.75±0.54 | 0.520 | 14.44±0.46 | 0.169 |
较高干扰组 | 15.74±0.77 | 0.585 | 14.49±0.52 | 0.213 |
高干扰组 | 15.91±0.56 | 0.892 | 14.38±0.64 | 0.135 |
脂血组 | ||||
低干扰组 | 14.43±0.52 | 0.000 | 14.12±0.55 | 0.011 |
中度干扰组 | 14.37±0.44 | 0.000 | 13.89±0.62 | 0.000 |
较高干扰组 | 14.61±0.24 | 0.001 | 14.26±0.37 | 0.049 |
高干扰组 | 14.31±0.41 | 0.000 | 13.93±0.46 | 0.001 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
突变ΔCt值 | P值 | 突变ΔCt值 | P值 | |
空白组 | 4.84±0.61 | -0.42±0.49 | ||
黄疸组 | ||||
低干扰组 | 4.94±0.86 | 0.766 | -0.65±0.30 | 0.087 |
中度干扰组 | 4.59±1.15 | 0.560 | -0.56±0.50 | 0.393 |
较高干扰组 | 4.55±1.02 | 0.449 | -0.51±0.33 | 0.567 |
高干扰组 | 4.61±1.48 | 0.700 | -0.54±0.34 | 0.262 |
溶血组 | ||||
低干扰组 | 5.11±0.71 | 0.275 | -0.64±0.33 | 0.081 |
中度干扰组 | 4.83±0.99 | 0.976 | -0.71±0.37 | 0.007 |
较高干扰组 | 4.69±0.94 | 0.579 | -0.73±0.28 | 0.034 |
高干扰组 | 4.68±0.77 | 0.463 | -0.85±0.30 | 0.011 |
脂血组 | ||||
低干扰组 | 5.64±0.60 | 0.011 | -0.80±0.36 | 0.008 |
中度干扰组 | 5.55±0.42 | 0.008 | -0.99±0.26 | 0.043 |
较高干扰组 | 5.88±0.33 | 0.000 | -0.89±0.38 | 0.003 |
高干扰组 | 5.75±0.55 | 0.000 | -0.52±0.26 | 0.507 |
组别 | T790M临界阳性 | T790M强阳性 | ||
---|---|---|---|---|
突变ΔCt值 | P值 | 突变ΔCt值 | P值 | |
空白组 | 4.84±0.61 | -0.42±0.49 | ||
黄疸组 | ||||
低干扰组 | 4.94±0.86 | 0.766 | -0.65±0.30 | 0.087 |
中度干扰组 | 4.59±1.15 | 0.560 | -0.56±0.50 | 0.393 |
较高干扰组 | 4.55±1.02 | 0.449 | -0.51±0.33 | 0.567 |
高干扰组 | 4.61±1.48 | 0.700 | -0.54±0.34 | 0.262 |
溶血组 | ||||
低干扰组 | 5.11±0.71 | 0.275 | -0.64±0.33 | 0.081 |
中度干扰组 | 4.83±0.99 | 0.976 | -0.71±0.37 | 0.007 |
较高干扰组 | 4.69±0.94 | 0.579 | -0.73±0.28 | 0.034 |
高干扰组 | 4.68±0.77 | 0.463 | -0.85±0.30 | 0.011 |
脂血组 | ||||
低干扰组 | 5.64±0.60 | 0.011 | -0.80±0.36 | 0.008 |
中度干扰组 | 5.55±0.42 | 0.008 | -0.99±0.26 | 0.043 |
较高干扰组 | 5.88±0.33 | 0.000 | -0.89±0.38 | 0.003 |
高干扰组 | 5.75±0.55 | 0.000 | -0.52±0.26 | 0.507 |
[1] | 段纪俊,严亚琼,杨念念,等. 中国恶性肿瘤发病与死亡的国际比较分析[J]. 中国医学前沿杂志(电子版),2016,8(7):17-23. |
[2] | LIANG Z,CHENG Y,CHEN Y,et al.EGFR T790M ctDNA testing platforms and their role as companion diagnostics:correlation with clinical outcomes to EGFR-TKIs[J]. Cancer Lett,2017,403:186-194. |
[3] | ALIX-PANABIÈRES C,PANTEL K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov,2016,6(5):479-491. |
[4] | 林铖,姜傥. 液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用[J]. 检验医学,2016,31(10):835-843. |
[5] | ROLFO C,CASTIGLIA M,HONG D,et al.Liquid biopsies in lung cancer:the new ambrosia of researchers[J]. Biochim Biophys Acta,2014,1846(2):539-546. |
[6] | 胥明勇,吴泳桦,朱华强. PCR抑制物干扰HBV DNA试剂检测能力评价[J]. 四川医学,2019,40(5):522-524. |
[7] | 中华人民共和国国家卫生和计划生育委员会. WS/T 416—2013 干扰实验指南[S]. 北京:中华人民共和国国家卫生和计划生育委员会,2013. |
[8] | 尚红,王毓三,申子瑜. 全国临床检验操作规程[M]. 4版. 北京:人民卫生出版社,2015. |
[9] | PAO W,MILLER V A,POLITI K A,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Med,2005,2(3):e73. |
[10] | DIAZ L A Jr,BARDELLI A. Liquid biopsies:genotyping circulating tumor DNA[J]. J Clin Oncol,2014,32(6):579-586. |
[11] | DUAN H,LU J,LU T,et al.Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status[J]. Int J Clin Exp Pathol,2015,8(10):13136-13145. |
[12] | PFISTER D G,JOHNSON D H,AZZOLI C G,et al.American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:update 2003[J]. J Clin Oncol,2004,22(2):330-353. |
[13] | 卢鉴财,黄俊,徐韫健,等. Super-ARMS法在检测非小细胞肺癌EGFR基因突变中的应用分析[J]. 热带医学杂志,2019,19(4):430-433. |
[14] | 李顺君,左玥. 临床血液标本不合格的原因及干预措施有效性分析[J]. 检验医学与临床,2019,16(4):536-539. |
[15] | 袁凤喜,薛雄燕,陈彩凤,等. 溶血对液相色谱串联质谱检测血浆中儿茶酚胺及其代谢产物的影响[J]. 检验医学,2018,33(12):1103-1107. |
[16] | 沈克锋,杨默,江千里. 血液和骨髓标本中常见PCR反应抑制物的探究与分析[J]. 中国实验血液学杂志,2014,22(3):842-846. |
[17] | OZDARENDELI A,TOROMAN Z A,BULUT Y,et al.Combined branched-DNA and conventional HBV PCR assays for detection of serum HBV-DNA in hepatitis B E antigen-positive chronic hepatitis B patients[J]. Hepatogastroenterology,2006,53(67):106-109. |
[18] | 刘小敏,唐恒锋,李文郎,等. 高脂血、溶血标本对荧光定量聚合酶链反应测定低水平HBV-DNA的影响[J]. 检验医学与临床,2015,12(21):3217-3218. |
[19] | PORTILHO M M,MARTINS P P,LAMPE E,et al.A comparison of molecular methods for hepatitis B virus(HBV) DNA detection from oral fluid samples[J]. J Med Microbiol,2012,61(Pt 6):844-851. |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[3] | ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA1c,NT-proBNP,Hcy,SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286. |
[4] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[5] | WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881. |
[6] | XU Qianqian, JIANG Wangqing, SHEN Linjie, LU Yingjie, CHEN Jian, JIANG Haoqin. Establishment of the reference intervals for related parameters of adult reticulocytes in Shanghai [J]. Laboratory Medicine, 2022, 37(7): 641-645. |
[7] | MENG Shuting, ZHOU Weiping, DAI Huifen, DONG Deping, DONG Yefeng, GE Renmei, WANG Huimin. Evaluation of uncertainty of serum total bilirubin in calibration curve method by Monte Carlo method [J]. Laboratory Medicine, 2022, 37(7): 674-679. |
[8] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[9] | CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341. |
[10] | HONG Jun, RAO Yongcai. Establishment and evaluation of CD157-based 4-color PNH assay for neutrophil and monocyte by flow cytometry [J]. Laboratory Medicine, 2022, 37(4): 377-381. |
[11] | XUE Yan, XU Li, DANG Liheng, WANG Chao, CUI Yaqiong, WANG Ping, WANG Ning, ZHANG Xinjie, LIU Yang. Interference of high levels of bilirubin on lymphocyte subset determination in peripheral blood by flow cytometry and its elimination methods [J]. Laboratory Medicine, 2022, 37(12): 1169-1173. |
[12] | QU Yuanqing, ZHAO Fan, YE Ailian, LI Lifeng, ZHAO Haitao, LI Huizhen, LIANG Zhuohui, LI Liang. Relationship between plasma omentin-1 level and metabolic clearance rate in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2022, 37(1): 28-31. |
[13] | MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46. |
[14] | YUE Daoyuan, CHEN Wei, LIAO Qing, YU Weiting, LI Huijun. Establishment and evaluation of Wuhan Glycohemoglobin Harmonization Program [J]. Laboratory Medicine, 2022, 37(1): 78-82. |
[15] | YU Ting, SHEN Min, QU Shoufang, SUN Nan, SUN Jing, HUANG Jie. Development of the national standard materials of total bilirubin in frozen human serum [J]. Laboratory Medicine, 2021, 36(9): 957-961. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||